Skip to main content
All lobbying filings

DRUG POLICY ALLIANCE

Lobbying for DRUG POLICY ALLIANCE

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 17, 2026
Expenses
$18,639
What this organization spent lobbying with its own staff. Reported using IRS section 6033(b)(8) definitions (method B): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New York

Official filing document

 Lobbyists on this filing 1
  • HANNA SHARIF-KAZEMI
    Previously held: Policy Manager

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Lobbying activity 3
Law Enforcement/Crime/Criminal Justice

We urged Congress to support and co-sponsor the MORE Act (H.R. 5068). We urged Congress to support and co-sponsor the Cannabis Administration and Opportunity Act in the Senate. We urged Congress to oppose the Combating Xylazine Act(H.R. 1266/S. 545), Nitazene Control Act (H.R. 5415 /S. 3076), and STOP Nitazenes Act (H.R. 7970).

Civil Rights/Civil Liberties

We urged Congress to support the RESTORE Act (H.R. 5223), a bill that would end the SNAP drug felony ban. We urged Congress to repeal the Thurmond Amendment to end housing discrimination via a bill called the Fair Future Act (H.R. 7765).

Health Issues

We urged Congress to fully fund health programs that support people struggling with addiction in Congressional spending bills (LHHS FY27 appropriations bills). We opposed the inclusion of a rider to ban overdose prevention centers in Congressional spending bills.

 Bills named in this filing 8

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem